SI3018145T1 - Sredstva in metode za zdravljenje dlbcl - Google Patents
Sredstva in metode za zdravljenje dlbcl Download PDFInfo
- Publication number
- SI3018145T1 SI3018145T1 SI201131489T SI201131489T SI3018145T1 SI 3018145 T1 SI3018145 T1 SI 3018145T1 SI 201131489 T SI201131489 T SI 201131489T SI 201131489 T SI201131489 T SI 201131489T SI 3018145 T1 SI3018145 T1 SI 3018145T1
- Authority
- SI
- Slovenia
- Prior art keywords
- composition
- dose
- use according
- time period
- dlbcl
- Prior art date
Links
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 title claims abstract 5
- 238000000034 method Methods 0.000 title claims abstract 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims abstract 4
- 206010025323 Lymphomas Diseases 0.000 claims abstract 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 210000001165 lymph node Anatomy 0.000 claims 3
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 abstract 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Carbon And Carbon Compounds (AREA)
Claims (14)
1. Sestava, ki vsebuje bispecifično protitelo CD19xCD3 za uporabo pri metodi zdravljenja tumorske mase tkiva limfnih vozlov in/ali ekstranodalnega limfoma, ki ga povzroča difuzni velikocelični limfom B (DLBCL) pri bolniku, pri katerem je rak odporen proti kemoterapevtskemu zdravljenju in/ali recidiven po zdravljenju s kemoterapijo.
2. Sestava za uporabo v skladu s patentnim zahtevkom 1, pri čemer je za tumorsko maso značilno, da so tumorji večji od 10 x 10 mm.
3. Sestava za uporabo v skladu s patentnim zahtevkom 1 ali 2, pri čemer tkivo limfnih vozlov vključuje bezgavke in/ali vranico.
4. Sestava za uporabo v skladu s patentnim zahtevkom 1 ali 2, pri čemer ekstranodalni limfom vključuje osrednji živčni sistem (CNS), kožno tkivo, dojke, pljuča, jetra, gastrointestinalni trakt, genitourinarni trakt, očesno tkivo, kostni mozeg in/ali kosti.
5. Sestava za uporabo iz katerega koli prejšnjega patentnega zahtevka, pri čemer se prvi odmerek sestava dovaja za prvo časovno obdobje in nato se drugi odmerek sestava dovaja za drugo časovno obdobje, pri čemer drugi odmerek presega prvega.
6. Sestava za uporabo v skladu s patentnim zahtevkom 5, pri čemer je omenjeni prvi odmerek med 1 in 15 pg/m2/d.
7. Sestava za uporabo v skladu s patentnim zahtevkom 5 ali 6, pri čemer je omenjeni drugi odmerek med 15 in 60 pg/m2/d.
8. Sestava za uporabo v skladu s patentnim zahtevkom 5, ki po prvem in drugem odmerku za prvo in drugo časovno obdobje nadalje obsega dovajanje tretjega odmerka sestava za tretje časovno obdobje.
9. Sestava za uporabo v skladu s patentnim zahtevkom 8, pri čemer tretje časovno obdobje presega prvo in drugo časovno obdobje, v katerem drugi odmerek presega navedeni prvi odmerek.
10. Sestava za uporabo v skladu s patentnim zahtevkom 8 ali 9, pri čemer tretji odmerek presega prvi in drugi odmerek.
11. Sestava za uporabo v skladu s katerim koli patentnim zahte
navedeni prvi odmerek med 1 in 15 pg/m2/d oz. prednostno 5 pg/m2/d.
12. Sestava za uporabo v skladu s katerim koli patentnim zahtevkom od 8 do 11, pri čemer je navedeni drugi odmerek med 1 in 15 pg/m2/d oz. prednostno 15 pg/m2/d.
13. Sestava za uporabo v skladu s katerim koli patentnim zahtevkom od 8 do 12, pri čemer je navedeni tretji odmerek med 15 in 60 pg/m2/d oz. prednostno 60 pg/m2/d.
14. Sestava za uporabo v skladu s katerim koli od patentnih zahtevkov od 1 do 4, pri čemer je protitelo med zdravljenjem odmerjeno v konstantnem odmerku, izbranem iz skupine, ki sestoji iz 5 pg/m2/d, 15 pg/m2/d ali 60 pg/m2/d oz. prednostno 60 pg/m2/d.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40710710P | 2010-10-27 | 2010-10-27 | |
| EP15195076.3A EP3018145B1 (en) | 2010-10-27 | 2011-10-27 | Means and methods for treating dlbcl |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3018145T1 true SI3018145T1 (sl) | 2018-08-31 |
Family
ID=45023802
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201130709T SI2632954T2 (sl) | 2010-10-27 | 2011-10-27 | Sredstva in postopki za zdravljenje dlbcl |
| SI201131489T SI3018145T1 (sl) | 2010-10-27 | 2011-10-27 | Sredstva in metode za zdravljenje dlbcl |
| SI201131861T SI3412687T1 (sl) | 2010-10-27 | 2011-10-27 | Postopek zdravljenja DLBCL |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201130709T SI2632954T2 (sl) | 2010-10-27 | 2011-10-27 | Sredstva in postopki za zdravljenje dlbcl |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201131861T SI3412687T1 (sl) | 2010-10-27 | 2011-10-27 | Postopek zdravljenja DLBCL |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US9192665B2 (sl) |
| EP (3) | EP3412687B1 (sl) |
| JP (3) | JP5997168B2 (sl) |
| KR (1) | KR101889995B1 (sl) |
| CN (2) | CN103459425B (sl) |
| AU (1) | AU2011322581B2 (sl) |
| CA (1) | CA2815119C (sl) |
| CL (1) | CL2013001138A1 (sl) |
| CR (1) | CR20130245A (sl) |
| CY (3) | CY1117155T1 (sl) |
| DK (3) | DK2632954T4 (sl) |
| EA (1) | EA032139B1 (sl) |
| ES (3) | ES2675299T3 (sl) |
| HR (2) | HRP20151444T4 (sl) |
| HU (3) | HUE048639T2 (sl) |
| IL (3) | IL225924A (sl) |
| LT (2) | LT3412687T (sl) |
| MA (1) | MA34619B1 (sl) |
| ME (1) | ME02311B (sl) |
| MY (1) | MY163057A (sl) |
| NZ (2) | NZ701715A (sl) |
| PH (1) | PH12013500826A1 (sl) |
| PL (3) | PL3018145T3 (sl) |
| PT (3) | PT2632954E (sl) |
| RS (3) | RS57260B1 (sl) |
| SG (1) | SG189869A1 (sl) |
| SI (3) | SI2632954T2 (sl) |
| SM (3) | SMT201800319T1 (sl) |
| TR (1) | TR201808019T4 (sl) |
| UA (1) | UA111175C2 (sl) |
| WO (1) | WO2012055961A1 (sl) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2606081C (en) | 2005-04-26 | 2013-09-17 | Markus M. Heiss | Combination of the application of antibodies for immunostimulation together with glucocorticoids |
| EP3412687B1 (en) * | 2010-10-27 | 2020-03-18 | Amgen Research (Munich) GmbH | Methods for treating dlbcl |
| EP3831386A1 (en) * | 2010-11-10 | 2021-06-09 | Amgen Research (Munich) GmbH | Prevention of adverse effects caused by cd3 specific binding domains |
| JO3529B1 (ar) * | 2013-02-08 | 2020-07-05 | Amgen Res Munich Gmbh | مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد |
| ES2845924T3 (es) | 2013-10-15 | 2021-07-28 | Scripps Research Inst | Interruptores de células T con receptores de antígenos quiméricos peptídicos y usos de los mismos |
| US10800828B2 (en) | 2015-03-26 | 2020-10-13 | The Scripps Research Institute | Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer |
| EP3283113A4 (en) | 2015-04-15 | 2018-12-05 | The California Institute for Biomedical Research | Optimized pne-based chimeric receptor t cell switches and uses thereof |
| CA2986254A1 (en) | 2015-05-18 | 2016-11-24 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| MX2018004515A (es) * | 2015-10-13 | 2019-04-15 | Eureka Therapeutics Inc | Agentes de anticuerpo especificos para cd19 humano y usos de los mismos. |
| JP2019532017A (ja) * | 2016-07-14 | 2019-11-07 | フレッド ハッチンソン キャンサー リサーチ センター | がんを治療するための異なるエピトープ結合を示す複数の二重特異性結合ドメイン構築物 |
| EP3494138A1 (en) | 2016-08-02 | 2019-06-12 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| JP7217970B2 (ja) | 2016-10-07 | 2023-02-06 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いてｔ細胞受容体をリプログラミングするための組成物及び方法 |
| KR20230172612A (ko) | 2016-10-19 | 2023-12-22 | 더 스크립스 리서치 인스티튜트 | 인간화된 표적화 모이어티 및/또는 최적화된 키메라 항원 수용체-상호작용 도메인을 갖는 키메라 항원 수용체 효과기 세포 스위치 및 이의 용도 |
| CN110177803A (zh) | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| US11865081B2 (en) | 2017-12-29 | 2024-01-09 | Virogin Biotech Canada Ltd. | Oncolytic viral delivery of therapeutic polypeptides |
| US20220023430A1 (en) * | 2018-11-13 | 2022-01-27 | Lipoxen Technologies Limited | Glycopolysialylation of blinatumomab |
| US20200384027A1 (en) * | 2019-05-03 | 2020-12-10 | Kite Pharma, Inc. | Methods of administering chimeric antigen receptor immunotherapy |
| KR20230031981A (ko) | 2019-05-14 | 2023-03-07 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| EP3972998A1 (en) | 2019-05-21 | 2022-03-30 | Novartis AG | Cd19 binding molecules and uses thereof |
| AU2021287998A1 (en) | 2020-06-11 | 2023-02-02 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| MX2023006538A (es) * | 2020-12-04 | 2023-08-08 | Morphosys Ag | Terapia combinada de anticuerpo anti cúmulo de diferenciación 19 (cd19). |
| JP2024506831A (ja) | 2021-01-28 | 2024-02-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | サイトカイン放出症候群を治療するための組成物及び方法 |
| IL316002A (en) | 2022-04-11 | 2024-11-01 | Regeneron Pharma | Compositions and methods for universal tumor cell killing |
| AU2024223918A1 (en) | 2023-02-17 | 2025-09-11 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
| PL199747B1 (pl) | 1998-04-21 | 2008-10-31 | Micromet Ag | Jednołańcuchowy wielofunkcyjny polipeptyd, polinukleotyd, wektor, komórka, sposób wytwarzania polipeptydu, kompozycja, zastosowanie polipeptydu lub wektora lub polinukleotydu i zastosowanie polinukleotydu lub wektora oraz sposób identyfikacji aktywatorów lub inhibitorów aktywacji lub stymulacji komórek T |
| WO2004106381A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| WO2005052004A2 (en) | 2003-11-28 | 2005-06-09 | Micromet Ag | Compositions comprising polypeptides |
| KR101289537B1 (ko) | 2005-02-15 | 2013-07-31 | 듀크 유니버시티 | 항-ｃｄ19 항체 및 종양학에서 이의 용도 |
| CA2606081C (en) * | 2005-04-26 | 2013-09-17 | Markus M. Heiss | Combination of the application of antibodies for immunostimulation together with glucocorticoids |
| DK1976886T3 (en) * | 2005-12-16 | 2015-03-02 | Amgen Res Munich Gmbh | Means and methods for the treatment of tumor diseases |
| CN101331151A (zh) * | 2005-12-16 | 2008-12-24 | 麦克罗梅特股份公司 | 治疗肿瘤性疾病的方式和方法 |
| DK2066349T3 (da) | 2006-09-08 | 2012-07-09 | Medimmune Llc | Humaniseret anti-cd19-antistoffer og anvendelse heraf i behandling af tumorer, transplantation og autoimmune sygdomme |
| BRPI0809594A2 (pt) | 2007-04-03 | 2019-08-27 | Micromet Ag | polipeptídeo, seqüência de ácido nucléico, vetor, hospedeiro, processo para a produção de um polipeptídeo, composição farmacêutica, uso de um polipeptídeo, método para prevenção, tratamento ou melhora de uma doença, em um indivíduo com necessidade do mesmo, kit, método para a identificação de um polipeptídeo(s) |
| AU2009313040B2 (en) * | 2008-11-07 | 2015-07-09 | Amgen Research (Munich) Gmbh | Treatment of acute lymphoblastic leukemia |
| RU2548746C2 (ru) * | 2009-10-27 | 2015-04-20 | Эмджен Рисерч (Мьюник), ГмбХ | Режим дозирования для введения биспецифичного антитела cd19×cd3 |
| EP3412687B1 (en) * | 2010-10-27 | 2020-03-18 | Amgen Research (Munich) GmbH | Methods for treating dlbcl |
-
2011
- 2011-10-27 EP EP18164175.4A patent/EP3412687B1/en not_active Revoked
- 2011-10-27 SM SM20180319T patent/SMT201800319T1/it unknown
- 2011-10-27 HU HUE18164175A patent/HUE048639T2/hu unknown
- 2011-10-27 NZ NZ701715A patent/NZ701715A/en unknown
- 2011-10-27 TR TR2018/08019T patent/TR201808019T4/tr unknown
- 2011-10-27 RS RS20180624A patent/RS57260B1/sr unknown
- 2011-10-27 SI SI201130709T patent/SI2632954T2/sl unknown
- 2011-10-27 MA MA35841A patent/MA34619B1/fr unknown
- 2011-10-27 LT LTEP18164175.4T patent/LT3412687T/lt unknown
- 2011-10-27 PL PL15195076T patent/PL3018145T3/pl unknown
- 2011-10-27 DK DK11787633.4T patent/DK2632954T4/da active
- 2011-10-27 LT LTEP15195076.3T patent/LT3018145T/lt unknown
- 2011-10-27 UA UAA201306486A patent/UA111175C2/uk unknown
- 2011-10-27 JP JP2013535437A patent/JP5997168B2/ja active Active
- 2011-10-27 ES ES15195076.3T patent/ES2675299T3/es active Active
- 2011-10-27 HR HRP20151444TT patent/HRP20151444T4/hr unknown
- 2011-10-27 PT PT117876334T patent/PT2632954E/pt unknown
- 2011-10-27 CN CN201180063222.2A patent/CN103459425B/zh active Active
- 2011-10-27 RS RS20160027A patent/RS54525B2/sr unknown
- 2011-10-27 KR KR1020137013384A patent/KR101889995B1/ko active Active
- 2011-10-27 DK DK18164175.4T patent/DK3412687T3/da active
- 2011-10-27 SI SI201131489T patent/SI3018145T1/sl unknown
- 2011-10-27 HU HUE15195076A patent/HUE037786T2/hu unknown
- 2011-10-27 ES ES18164175T patent/ES2787044T3/es active Active
- 2011-10-27 ES ES11787633T patent/ES2563439T5/es active Active
- 2011-10-27 RS RS20200368A patent/RS60094B1/sr unknown
- 2011-10-27 US US13/881,889 patent/US9192665B2/en active Active
- 2011-10-27 MY MYPI2013001269A patent/MY163057A/en unknown
- 2011-10-27 WO PCT/EP2011/068851 patent/WO2012055961A1/en not_active Ceased
- 2011-10-27 PL PL11787633T patent/PL2632954T5/pl unknown
- 2011-10-27 PH PH1/2013/500826A patent/PH12013500826A1/en unknown
- 2011-10-27 EP EP15195076.3A patent/EP3018145B1/en active Active
- 2011-10-27 SM SM20200232T patent/SMT202000232T1/it unknown
- 2011-10-27 NZ NZ609201A patent/NZ609201A/en unknown
- 2011-10-27 AU AU2011322581A patent/AU2011322581B2/en active Active
- 2011-10-27 CN CN201510672546.6A patent/CN105251003B/zh active Active
- 2011-10-27 ME MEP-2015-213A patent/ME02311B/me unknown
- 2011-10-27 HU HUE11787633A patent/HUE027678T2/en unknown
- 2011-10-27 EP EP11787633.4A patent/EP2632954B2/en active Active
- 2011-10-27 EA EA201390387A patent/EA032139B1/ru not_active IP Right Cessation
- 2011-10-27 DK DK15195076.3T patent/DK3018145T3/en active
- 2011-10-27 PL PL18164175T patent/PL3412687T3/pl unknown
- 2011-10-27 SG SG2013026828A patent/SG189869A1/en unknown
- 2011-10-27 CA CA2815119A patent/CA2815119C/en active Active
- 2011-10-27 PT PT151950763T patent/PT3018145T/pt unknown
- 2011-10-27 SI SI201131861T patent/SI3412687T1/sl unknown
- 2011-10-27 PT PT181641754T patent/PT3412687T/pt unknown
-
2013
- 2013-04-24 IL IL225924A patent/IL225924A/en active IP Right Grant
- 2013-04-25 CL CL2013001138A patent/CL2013001138A1/es unknown
- 2013-05-27 CR CR20130245A patent/CR20130245A/es unknown
-
2015
- 2015-10-16 US US14/885,404 patent/US10696744B2/en active Active
-
2016
- 2016-01-29 CY CY20161100083T patent/CY1117155T1/el unknown
- 2016-02-17 SM SM201600050T patent/SMT201600050B/xx unknown
- 2016-06-01 JP JP2016110083A patent/JP6254220B2/ja active Active
-
2017
- 2017-11-29 JP JP2017228716A patent/JP6522722B2/ja active Active
- 2017-12-05 IL IL256110A patent/IL256110B/en active IP Right Grant
-
2018
- 2018-05-16 CY CY20181100508T patent/CY1120227T1/el unknown
- 2018-06-05 HR HRP20180882TT patent/HRP20180882T1/hr unknown
- 2018-07-25 IL IL260774A patent/IL260774B/en active IP Right Grant
-
2020
- 2020-05-08 CY CY20201100425T patent/CY1123251T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3018145T1 (sl) | Sredstva in metode za zdravljenje dlbcl | |
| Canter et al. | Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial | |
| Vuckovic et al. | Bone marrow transplantation generates T cell–dependent control of myeloma in mice | |
| Lu et al. | TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy | |
| NZ619576A (en) | Compositions and methods for the treatment of infections and tumors | |
| PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| MX2024013016A (es) | Anticuerpos anti-pd1 para usarse en el tratamiento del cancer | |
| RU2017145558A (ru) | Комбинация антагониста pd-1 и олигонуклеотида типа cpg-c для лечения рака | |
| JP2018516911A5 (sl) | ||
| BR112017019785A2 (pt) | anticorpos terapêuticos e seus usos | |
| EA201171195A1 (ru) | Конъюгаты, частицы, композиции "полимер-агент" и способы их применения | |
| WO2012149412A3 (en) | Anti-endoglin (cd105) antibodies, immunoconjugates, and uses thereof | |
| EP4335511A3 (en) | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy | |
| PH12020551447A1 (en) | Antibodies | |
| WO2021062272A3 (en) | Analysis methods for multiplex tissue imaging including imaging mass cytometry data | |
| D’Alterio et al. | New CXCR4 antagonist peptide R (Pep R) improves standard therapy in colorectal cancer | |
| EP4424321A3 (en) | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies | |
| WO2021092555A3 (en) | Methods of screening to determine effective dosing of cancer therapeutics | |
| RU2014145234A (ru) | Система и способ для многофазного высвобождения факторов роста | |
| MX2021003047A (es) | Nanosondas ups de doble modalidad para imagenologia de acidosis tumoral. | |
| Obertopp et al. | Local single-dose radiation improves adoptive cell therapy with tumor infiltrating lymphocytes | |
| Forment | 129 speaker ABSCOPAL IMMUNE RESPONSE LINKED TO RADIOTHERAPY | |
| Valenlini | 130 speaker CAN SMALL DOSES OF RADIATION ENHANCE CHEMOTHERAPY IN ADVANCED PATIENTS? | |
| Lartigau | 128 speaker IMPROVING THE OUTCOME WITH CURATIVE HIGH PRECISION RADIOTHERAPY FOR METASTATIC PATIENTS? | |
| Liu et al. | Combining PIM‐2 and PARP1 Inhibitors Induces MICA Expression on Multiple Myeloma Cells to Activate NK Cells through NKG2D Binding |